Compare ETON & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | GMRE |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 449.5M |
| IPO Year | 2018 | N/A |
| Metric | ETON | GMRE |
|---|---|---|
| Price | $16.27 | $33.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $29.67 | ★ $40.50 |
| AVG Volume (30 Days) | ★ 211.3K | 124.2K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 8.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $70,316,000.00 | ★ $144,829,000.00 |
| Revenue This Year | $107.23 | $7.49 |
| Revenue Next Year | $29.72 | $3.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | 6.04 |
| 52 Week Low | $11.09 | $29.05 |
| 52 Week High | $23.00 | $45.75 |
| Indicator | ETON | GMRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 53.00 |
| Support Level | $16.53 | $32.90 |
| Resistance Level | $17.33 | $34.09 |
| Average True Range (ATR) | 0.64 | 0.60 |
| MACD | 0.08 | -0.21 |
| Stochastic Oscillator | 32.91 | 32.41 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.